Premium
SpringWorks Therapeutics Inc (SWTX)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differenti... SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. Show more
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
– Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors...
– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib...
– Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN – – Patients achieved deep and durable...
– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with...
STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.48 | -1.31291028446 | 36.56 | 37.3999 | 35.39 | 603321 | 36.45051846 | CS |
| 4 | -5.77 | -13.7873357228 | 41.85 | 42.94 | 34.355 | 955122 | 37.921957 | CS |
| 12 | 5.4 | 17.6010430248 | 30.68 | 44.92 | 28.21 | 1120420 | 35.50771599 | CS |
| 26 | -2.29 | -5.9682043263 | 38.37 | 44.92 | 28.21 | 994800 | 35.91273526 | CS |
| 52 | -0.02 | -0.0554016620499 | 36.1 | 53.92 | 28.21 | 1000808 | 40.3642927 | CS |
| 156 | -25.88 | -41.7688831504 | 61.96 | 66.115 | 13.6 | 866913 | 33.75038604 | CS |
| 260 | -2.41 | -6.26136658872 | 38.49 | 96.48 | 13.6 | 623051 | 38.6928302 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
